The SURMOUNT-1 obesity trial
In adults with obesity or overweight without diabetes, tirzepatide produced substantial, dose-dependent weight loss over 72 weeks versus placebo (SURMOUNT-1 phase 3 trial).
- Study type
- Human trial
- Population
- Adults with BMI 30 or above (or 27 or above with 1 or more weight-related comorbidity), without diabetes; phase 3, double-blind, placebo-controlled, multicentre.
- Source
- 1 Jastreboff et al., 2022
Limitation: Sponsor-funded (Eli Lilly); dose-dependent gastrointestinal adverse events are the main tolerability constraint reported alongside efficacy.